Related Experiment Video
Updated: Nov 18, 2025
08:33
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
Published on: January 5, 2024
1.5K
The Clinical Difference between Gabapentin and Pregabalin: Data from a Pilot Comparative Trial.
Omar Gammoh1, Ahmed Al-Smadi2, Mohammad Q Shawagfeh3
1Faculty of Health Sciences, American University of Madaba, Amman, Jordan.
Reviews on Recent Clinical Trials
|February 10, 2021
Summary
In low back pain management, pregabalin significantly reduced pain scores more than gabapentin. However, gabapentin showed greater improvements in anxiety, insomnia, and fatigue symptoms.
Area of Science:
- Neurology
- Pain Management
- Pharmacology
Background:
- Gabapentin and pregabalin are anticonvulsants used for neuropathic pain.
- Clinical differences between gabapentin and pregabalin in low back pain are not well-established.
Purpose of the Study:
- To compare the clinical differences between gabapentin and pregabalin in patients with low back pain.
Main Methods:
- A randomized trial involving 64 patients with moderate to severe low back pain.
- Patients received either pregabalin (300 mg/day) or gabapentin (800 mg/day) for six weeks.
- Outcomes included pain intensity (Visual Analogue Score), anxiety, insomnia, fatigue, and global impression of change.
Main Results:
- Pregabalin group showed a significantly lower pain score (p=0.039).
- Gabapentin group demonstrated significant improvements in anxiety (p=0.001), insomnia (p=0.001), and fatigue (p=0.009).
- No significant difference was observed in the global impression of change between groups.
Conclusions:
- Pregabalin was superior in pain reduction for low back pain.
- Gabapentin showed better effects on associated anxiety, insomnia, and fatigue symptoms.
- Larger sample size studies are required due to preliminary findings.
Keywords:
Gabapentinanticonvulsantsglobal clinical impression (GCI).low back painneuropathic pain managementpilot comparative trialpregabalinMore Related Videos
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
423
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
423
01:24Local Anesthetics: Differential Sensitivity of Nerve Fibers
1.2K
Local anesthetics (LAs) block the sodium channels of nerve trunks, sensory nerve endings, and neuromuscular junctions. Although LAs can block all kinds of nerves, the sensitivity of nerve fibers differs according to nerve types and structures. LAs are known to block myelinated fibers faster than unmyelinated ones. Also, they block pain or sensory neurons at low concentrations without affecting the motor neurons involved in muscle contractions. This helps relieve labor pain without affecting the...
1.2K
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
4.1K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
4.1K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
936
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
936
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
605
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
605
01:29Anxiolytic Drugs: Benzodiazepines and Buspirone
1.8K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
1.8K